Early Approval for Abbott AIDS Medicine
(ABBOTT PARK, ILL)The Food and Drug Administration (FDA) has granted an early approval of the Abbott Laboratories' AIDS drug Kaletra, a form of protease inhibitor medication that has shown considerable promise in bringing the virus down to undetectable levels. Abbott applied for FDA approval on June 1, 2000 and was not expecting results until later this fall.
Kaletra is a mixture of two drugs, the main one generically called lopinavir and previously called ABT-378 in Abbott clinical labs, the other is ritonavir, already on the market as an AIDS drug under the brand name Norvir. For more information visit www.fda.gov.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
